Abstract
This article is a part of a JADPRO certified supplement, Optimizing Treatment and Improving Outcomes for Patients With Acute Myeloid Leukemia: A Guide for Advanced Practitioners
Table of Contents
Appendix: Key Information on Newly Approved AML Drugs
December 23, 2019
Volume 10, Supplement 4 (Nov/Dec 2019)
https://doi.org/10.6004/jadpro.2019.10.8.15
